View Financial HealthTechno Drugs 배당 및 자사주 매입배당 기준 점검 2/6Techno Drugs 수익으로 충분히 충당되는 현재 수익률 2.29% 보유한 배당금 지급 회사입니다.핵심 정보2.3%배당 수익률0%자사주 매입 수익률총 주주 수익률2.3%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향62%최근 배당 및 자사주 매입 업데이트공시 • Oct 30Techno Drugs Ltd. announces Annual dividend, payable on January 25, 2026Techno Drugs Ltd. announced Annual dividend of BDT 1.0000 per share payable on January 25, 2026, ex-date on November 20, 2025 and record date on November 19, 2025.공시 • Oct 29Techno Drugs Ltd. Recommends 12% Cash Dividend for the year ended June 30, 2024The Board of Directors of Techno Drugs Ltd. recommended 12% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: December 26, 2024.모든 업데이트 보기Recent updatesBoard Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.공시 • Apr 27Techno Drugs Ltd. to Report Q3, 2026 Results on Apr 29, 2026Techno Drugs Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026공시 • Jan 29Techno Drugs Ltd. to Report Q2, 2026 Results on Jan 31, 2026Techno Drugs Ltd. announced that they will report Q2, 2026 results on Jan 31, 2026공시 • Nov 09Techno Drugs Ltd. to Report Q1, 2026 Results on Nov 13, 2025Techno Drugs Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025공시 • Oct 30Techno Drugs Ltd. announces Annual dividend, payable on January 25, 2026Techno Drugs Ltd. announced Annual dividend of BDT 1.0000 per share payable on January 25, 2026, ex-date on November 20, 2025 and record date on November 19, 2025.공시 • Oct 29Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025, at 10:00 Central Asia Standard Time. Location: hybrid system in combination of physical, presence at institution of diploma engineers, l60/a, kakrail vip road, through the link., Bangladesh공시 • Oct 21Techno Drugs Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Techno Drugs Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025공시 • Apr 23Techno Drugs Ltd. to Report Q3, 2025 Results on Apr 29, 2025Techno Drugs Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025공시 • Jan 27Techno Drugs Ltd. to Report Q2, 2025 Results on Jan 30, 2025Techno Drugs Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025공시 • Nov 11Techno Drugs Ltd. to Report Q1, 2025 Results on Nov 14, 2024Techno Drugs Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024공시 • Oct 29Techno Drugs Ltd. Recommends 12% Cash Dividend for the year ended June 30, 2024The Board of Directors of Techno Drugs Ltd. recommended 12% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: December 26, 2024.Valuation Update With 7 Day Price Move • Oct 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ৳38.00, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 18x in the Pharmaceuticals industry in Bangladesh.공시 • Oct 22Techno Drugs Ltd. to Report Fiscal Year 2024 Results on Oct 27, 2024Techno Drugs Ltd. announced that they will report fiscal year 2024 results on Oct 27, 2024New Risk • Sep 27New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 46% over the past year. Minor Risk Market cap is less than US$100m (৳5.87b market cap, or US$49.0m).Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ৳40.50, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh.Board Change • Jul 14Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 배당금 지급이 안정적인 반면, TECHNODRUG 은(는) 배당금을 지급한 지 10년도 채 되지 않았습니다.배당금 증가: TECHNODRUG 2 년 동안만 배당금을 지급해 왔으며 그 이후 지급액이 감소했습니다.배당 수익률 vs 시장Techno Drugs 배당 수익률 vs 시장TECHNODRUG의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (TECHNODRUG)2.3%시장 하위 25% (BD)0.8%시장 상위 25% (BD)3.4%업계 평균 (Pharmaceuticals)3.8%분석가 예측 (TECHNODRUG) (최대 3년)n/a주목할만한 배당금: TECHNODRUG 의 배당금( 2.29% )은 BD 시장에서 배당금 지급자의 하위 25%( 0.76% )보다 높습니다.고배당: TECHNODRUG 의 배당금( 2.29% )은 BD 시장에서 배당금 지급자의 상위 25%( 3.44% )와 비교해 낮습니다.주주 대상 이익 배당수익 보장: 합리적인 지급 비율 ( 62.1% )을 통해 TECHNODRUG 의 배당금 지급은 수익으로 충당됩니다.주주 현금 배당현금 흐름 범위: TECHNODRUG 배당금을 지급하고 있지만 회사에는 잉여현금흐름이 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YBD 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/15 10:06종가2026/06/15 00:00수익2026/03/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Techno Drugs Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Oct 30Techno Drugs Ltd. announces Annual dividend, payable on January 25, 2026Techno Drugs Ltd. announced Annual dividend of BDT 1.0000 per share payable on January 25, 2026, ex-date on November 20, 2025 and record date on November 19, 2025.
공시 • Oct 29Techno Drugs Ltd. Recommends 12% Cash Dividend for the year ended June 30, 2024The Board of Directors of Techno Drugs Ltd. recommended 12% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: December 26, 2024.
Board Change • May 20Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.
공시 • Apr 27Techno Drugs Ltd. to Report Q3, 2026 Results on Apr 29, 2026Techno Drugs Ltd. announced that they will report Q3, 2026 results on Apr 29, 2026
공시 • Jan 29Techno Drugs Ltd. to Report Q2, 2026 Results on Jan 31, 2026Techno Drugs Ltd. announced that they will report Q2, 2026 results on Jan 31, 2026
공시 • Nov 09Techno Drugs Ltd. to Report Q1, 2026 Results on Nov 13, 2025Techno Drugs Ltd. announced that they will report Q1, 2026 results on Nov 13, 2025
공시 • Oct 30Techno Drugs Ltd. announces Annual dividend, payable on January 25, 2026Techno Drugs Ltd. announced Annual dividend of BDT 1.0000 per share payable on January 25, 2026, ex-date on November 20, 2025 and record date on November 19, 2025.
공시 • Oct 29Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025Techno Drugs Ltd., Annual General Meeting, Dec 24, 2025, at 10:00 Central Asia Standard Time. Location: hybrid system in combination of physical, presence at institution of diploma engineers, l60/a, kakrail vip road, through the link., Bangladesh
공시 • Oct 21Techno Drugs Ltd. to Report Fiscal Year 2025 Results on Oct 28, 2025Techno Drugs Ltd. announced that they will report fiscal year 2025 results on Oct 28, 2025
공시 • Apr 23Techno Drugs Ltd. to Report Q3, 2025 Results on Apr 29, 2025Techno Drugs Ltd. announced that they will report Q3, 2025 results on Apr 29, 2025
공시 • Jan 27Techno Drugs Ltd. to Report Q2, 2025 Results on Jan 30, 2025Techno Drugs Ltd. announced that they will report Q2, 2025 results on Jan 30, 2025
공시 • Nov 11Techno Drugs Ltd. to Report Q1, 2025 Results on Nov 14, 2024Techno Drugs Ltd. announced that they will report Q1, 2025 results on Nov 14, 2024
공시 • Oct 29Techno Drugs Ltd. Recommends 12% Cash Dividend for the year ended June 30, 2024The Board of Directors of Techno Drugs Ltd. recommended 12% Cash Dividend only for general shareholders other than Board of Directors for the year ended June 30, 2024. Directors/sponsor are holding 82,776,200 shares and General Public are holding 49,221,988 shares. Cash dividend payable to General Public is Tk. 59,066,386.00. Date of AGM: December 26, 2024.
Valuation Update With 7 Day Price Move • Oct 24Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ৳38.00, the stock trades at a trailing P/E ratio of 25.3x. Average trailing P/E is 18x in the Pharmaceuticals industry in Bangladesh.
공시 • Oct 22Techno Drugs Ltd. to Report Fiscal Year 2024 Results on Oct 27, 2024Techno Drugs Ltd. announced that they will report fiscal year 2024 results on Oct 27, 2024
New Risk • Sep 27New major risk - Financial data availabilityThe company's latest financial reports are more than a year old. Last reported fiscal period ended June 2023. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2023 fiscal period end). Interest payments are not well covered by earnings (2.0x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Revenue has declined by 46% over the past year. Minor Risk Market cap is less than US$100m (৳5.87b market cap, or US$49.0m).
Valuation Update With 7 Day Price Move • Sep 08Investor sentiment deteriorates as stock falls 19%After last week's 19% share price decline to ৳40.50, the stock trades at a trailing P/E ratio of 27x. Average trailing P/E is 24x in the Pharmaceuticals industry in Bangladesh.
Board Change • Jul 14Less than half of directors are independentFollowing the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 5 non-independent directors. Independent Director SK. Rahman was the last independent director to join the board, commencing their role in 2023. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model.